Search results for "Colorectal Neoplasms."

showing 10 items of 431 documents

Familial aggregation of tumors and detection of hereditary non-polyposis colorectal cancer in 3-year experience of 2 population-based colorectal-canc…

1995

The clinical data of 2 population-based registries, located in areas with different incidence rates of colorectal cancer, were used in order to assess the role of familial factors in the pathogenesis of these tumors. The occurrence of tumors in family members was investigated in 389 subjects with colorectal cancer registered in Modena (Northern Italy, an area characterized by a high incidence of colorectal malignancies) between 1984 and 1986; similar information was obtained in 213 patients with tumors of the large bowel registered in Ragusa (Sicily, Southern Italy, an area of similar magnitude and with low incidence rates for these tumors) in the 3-year period 1988 to 1990. In both series,…

MaleCancer Researchmedicine.medical_specialtyColorectal cancerPopulationRisk FactorsInternal medicineEpidemiologyPrevalenceMedicineHumansRegistriesRisk factoreducationAgedFamily Healtheducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceCancerFamily aggregationmedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisLynch syndromeSurgerynot availableOncologyItalyEvaluation Studies as TopicCase-Control StudiesFemalebusinessColorectal NeoplasmsInternational journal of cancer
researchProduct

Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study

2019

To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000-2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, a…

MaleCancer Researchmedicine.medical_specialtyColorectal cancerPrevalenceSocio-culturaleColonoscopyColorectal NeoplasmSettore MED/42 - Igiene Generale E Applicatacolorectal cancer screeningScreening programmeFeces03 medical and health sciences0302 clinical medicinecolonoscopyFaecal immunochemical test colonoscopy colorectal cancer screening epidemiology cancer registriesInternal medicineEpidemiologymedicineHumansStage (cooking)Early Detection of CancerAgedNeoplasm StagingProportional Hazards Modelscancer registriemedicine.diagnostic_testFaecal immunochemical testbusiness.industryIncidence (epidemiology)IncidenceMiddle Agedmedicine.diseaseImmunohistochemistryOncologyItalycancer registries030220 oncology & carcinogenesisRelative riskOccult BloodepidemiologyFeceFemaleNeoplasm GradingColorectal NeoplasmsbusinessHuman
researchProduct

Colorectal cancer stage at diagnosis in migrants versus non-migrants (KoMigra) : study protocol of a cross-sectional study in Germany

2014

Background: In Germany, about 20% of the total population have a migration background. Differences exist between migrants and non-migrants in terms of health care access and utilisation. Colorectal cancer is the second most common malignant tumour in Germany, and incidence, staging and survival chances depend, amongst other things, on ethnicity and lifestyle. The current study investigates whether stage at diagnosis differs between migrants and non-migrants with colorectal cancer in an area of high migration and attempts to identify factors that can explain any differences. Methods/Design: Data on tumour and migration status will be collected for 1,200 consecutive patients that have receive…

MaleCancer Researchmedicine.medical_specialtyCross-sectional studyLogistic regressionMigrantsHealth Services AccessibilityStudy ProtocolCross-sectionalGermanySurveys and QuestionnairesObservational studyHealth careEthnicityGeneticsHumansMedicineProspective Studiesddc:610Hard-to-reach populationProspective cohort studySocioeconomic statusAgedNeoplasm StagingTransients and MigrantsGynecologybusiness.industryOdds ratioMiddle AgedColorectal cancerCross-Sectional StudiesOncologyHealth care accessHard-to-reach population ; Ethnicity ; Observational study ; Migrants ; Colorectal cancer ; Health care access ; Cross-sectionalFemaleObservational studyOrdered logitColorectal NeoplasmsbusinessDemography
researchProduct

Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors.

2003

Outcome of patients with metastatic disease mainly depends on accurate preoperative tumor staging. 18[F]fluorodeoxyglucose positron emission tomography (18F-PET) has been proven to be a valuable diagnostic tool in a number of different tumors but its direct influence on liver surgery has not been thoroughly investigated. Between July 1999 and March 2000, 50 consecutive patients with 174 suspected liver lesions were admitted to the University Hospital Jena. All 50 patients underwent abdominal ultrasound, CT-scan, and 18-FDG positron emission tomography scanning. In 23 patients the diagnostic work-up was completed by MRI scan. Altogether there were a total of 174 histologically proven intrahe…

MaleCancer Researchmedicine.medical_specialtyFluorine RadioisotopesLiver tumorCarcinoma HepatocellularBreast NeoplasmsSensitivity and SpecificityResectionAdenoma Liver CellFluorodeoxyglucose positron emission tomographyFluorodeoxyglucose F18Internal medicinemedicineHumansMri scanNeoplasm StagingHematologymedicine.diagnostic_testbusiness.industryUltrasoundLiver NeoplasmsGeneral Medicinemedicine.diseaseUniversity hospitalOncologyPositron emission tomographyFemaleRadiologyRadiopharmaceuticalsbusinessNuclear medicineColorectal NeoplasmsFollow-Up StudiesTomography Emission-ComputedJournal of cancer research and clinical oncology
researchProduct

Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal ca…

2011

Abstract Purpose: An efficient adaptive immunity is critical for a longer survival in cancer. We investigated the prognostic value of tumor infiltration by CD8+ T cells expressing the chemokine-receptor-7 (Tccr7) and the correlation between tumor infiltration by Tccr7 and regulatory CD4+FoxP3+ T cells (Treg) in 76 metastatic colorectal cancer (mCRC) patients enrolled in a phase III trial. Experimental Design: Tccr7 and Treg cell infiltration in tumor samples was quantified by immunohistochemistry. The correlation among Tccr7, Treg tumor infiltration, and patients' outcome was evaluated. Results: High Tccr7 tumor infiltration was predictive of prolonged OS [high vs. low Tccr7 score: median 3…

MaleCancer Researchmedicine.medical_specialtyPathologyReceptors CCR7Colorectal cancerCD8 + T cellchemokine-receptor-7medicine.medical_treatmentchemical and pharmacologic phenomenacolorectal cancerKaplan-Meier EstimateAdenocarcinomaCD8-Positive T-LymphocytesGastroenterologyT-Lymphocytes RegulatoryDisease-Free SurvivalLymphocytes Tumor-InfiltratingT-Lymphocyte SubsetsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsCytotoxic T cellMedicineHumansAgedProportional Hazards ModelsChemotherapyTumor-infiltrating lymphocytesbusiness.industryFOXP3hemic and immune systemsmedicine.diseasePrognosisImmunohistochemistryTreatment OutcomeOncologyConcomitantFemaletumor infiltrating lymphocytes.businessColorectal NeoplasmsInfiltration (medical)CD8
researchProduct

Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.

2012

Cetuximab is a human-murine chimeric monoclonal antibody to the epidermal growth factor receptor, active for advanced colorectal cancer treatment in combination with chemotherapy. Cetuximab mainly acts by inhibiting epidermal growth factor receptor-mediated pathways in cancer cells; however, in the human host, its IgG1 backbone may offer additional antitumor activity that includes FcγRs-mediated antibody-dependent cell cytotoxicity, phagocytosis, cross priming, and tumor-specific T-cell-mediated immune response. These mechanisms are still under active investigation. At this purpose, we have performed an immunologic investigation in advanced colon cancer patients enrolled in an ongoing phase…

MaleCancer Researchmedicine.medical_treatmentCetuximabPharmacologyDeoxycytidineAldesleukinT-Lymphocyte SubsetsImmunology and AllergyCytotoxic T cellEpidermal growth factor receptorChemoimmunotherapybiologyCetuximabAntibodies MonoclonalMiddle AgedRecombinant ProteinsAdvanced Colorectal CancerErbB ReceptorsKiller Cells NaturalFemaleFluorouracilImmunotherapyAntibodyColorectal NeoplasmsImmune-modulating Effectmedicine.drugImmunologyAntineoplastic AgentsAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleImmunomodulationImmune systemCell Line TumormedicineHumansPharmacologyEpidermal growth factor receptorPolychemotherapybusiness.industryImmunotherapyDendritic CellsColorectal cancerGemcitabineCase-Control StudiesCancer cellbiology.proteinInterleukin-2CamptothecinbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

Immunoprofiles and DNA methylation of inflammatory marker genes in ulcerative colitis-associated colorectal tumorigenesis

2021

Immunological and epigenetic changes are interconnected and contribute to tumorigenesis. We determined the immunoprofiles and promoter methylation of inflammation-related genes for colitis-associated colorectal carcinomas (CA-CRC). The results were compared with Lynch syndrome (LS)-associated colorectal tumors, which are characterized by an active immune environment through inherited mismatch repair defects. CA-CRCs (n = 31) were immunohistochemically evaluated for immune cell scores (ICSs) and PDCD1 and CD274 expression. Seven inflammation-associated genes (CD274, NTSR1, PPARG, PTGS2, PYCARD, SOCS1, and SOCS2), the repair gene MGMT, and eight standard marker genes for the CpG Island Methyl…

MaleCarcinogenesismedicine.disease_causeBiochemistry0302 clinical medicineIntestinal MucosaDNA Modification Methylases0303 health sciencesMUCOSADNA methylationtulehdusinflammation-associated genesPYCARDMethylationMiddle AgedLynch syndromeQR1-502EPIGENETICS3. Good healthDNA-metylaatioGene Expression Regulation NeoplasticPhenotypecolon cancerepigenetiikka030220 oncology & carcinogenesisimmuunivasteDNA methylationFemaleColorectal NeoplasmsCANCERSINSTABILITYsuolistosyövätBiology3121 Internal medicineMicrobiologyArticle03 medical and health sciencesmedicineHumansEpigeneticsLynchin oireyhtymäMolecular Biologyneoplasms030304 developmental biologypaksusuolisyöpäulcerative colitisInflammationCpG Island Methylator PhenotypeTumor Suppressor Proteinshaavainen koliittimedicine.disease3126 Surgery anesthesiology intensive care radiologydigestive system diseasesDNA Repair EnzymesLynch syndrome3121 General medicine internal medicine and other clinical medicineMutationimmune cell scoreCancer research1182 Biochemistry cell and molecular biologyColitis UlcerativeCpG IslandsField cancerizationCarcinogenesisBiomarkers
researchProduct

A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer.

2015

Background Artesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experiments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects. Aim To determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CRC). Methods This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for curative resection of biopsy confirmed single primary site CRC were randomised (n = 23) by computer-generated code supplied in opaque envelopes to receive preoperatively either 14 daily doses of oral artesunate (200 mg; n = 12) or placebo (n = 11). The primary outcome meas…

MaleColorectal cancerResistancelcsh:MedicineAdministration OralArtesunatePilot ProjectsPharmacologyGastroenterologyPlacebosNeutropaeniachemistry.chemical_compoundCancerlcsh:R5-920medicine.diagnostic_testGeneral MedicineImmunohistochemistryArtemisininsDihydroartemisininTreatment OutcomeTolerabilityOriginal ArticleFemalelcsh:Medicine (General)Colorectal NeoplasmsKi67medicine.medical_specialtyRandomizationPlaceboGeneral Biochemistry Genetics and Molecular BiologyDouble-Blind MethodMedian follow-upInternal medicineBiopsymedicineBiomarkers TumorHumansAgedDemographyStaining and Labelingbusiness.industrylcsh:Rmedicine.diseaseColorectal cancerSurvival AnalysisCarcinoembryonic AntigenMalariaClinical trialKi-67 AntigenchemistryArtesunateCommentarybusinessEBioMedicine
researchProduct

Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammator…

2019

BACKGROUND Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined. METHODS In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis. RESULTS A total of 631 patients (late-onset 153, adult-onset 161, young adult-onset 317) were included. Colonic disease was more frequent in late-onset (P < 0005), stenosing behaviour was more frequent than in adult-onset (P < 0003), but fistulising disease was uncommon. Surgery rates were not different between the three age groups. Syste…

MaleDiseaseConstriction PathologictumoursInflammatory bowel diseaseLate Onset DisordersCohort Studiessurgery0302 clinical medicineCrohn DiseaseLate Onset DisordersMedicineYoung adultDigestive System Surgical ProceduresCrohn's diseaseGastroenterologyIleitisMiddle AgedColitisItaly030220 oncology & carcinogenesisoutcome030211 gastroenterology & hepatologyFemaleColorectal NeoplasmsCohort studysteroidsAdultmedicine.medical_specialtyAdolescentcomorbiditieselderly03 medical and health sciencesYoung AdultInternal medicineIntestinal FistulaHumansImmunologic FactorsGlucocorticoidsAgedRetrospective StudiesPolypharmacyHepatologybusiness.industrythiopurinesRetrospective cohort studymedicine.diseasecomorbidities; elderly; outcome; steroids; surgery; thiopurines; tumoursPolypharmacyTumor Necrosis Factor Inhibitorsbusiness
researchProduct

Factors associated with colorectal cancer in the context of the Mediterranean diet: a case-control study

2014

Recent evidence demonstrates that increased adherence to the Mediterranean diet (MD) may prevent colorectal cancer (CRC). The aim of this study was to evaluate the association between health-related characteristics and CRC in the context of the MD. This was a case-control study conducted on a sample of 338 consecutive patients with a first diagnosis of CRC recruited in an urban facility in the city of Catania, southern Italy, and matched with 676 apparently healthy subjects without clinical symptoms or signs of any type of cancer. Data regarding sociodemographic, clinical, and lifestyle characteristics were collected, and adherence to the Mediterranean diet pattern was assessed using the Me…

MaleGerontologyCancer Researchmedicine.medical_specialtySettore MED/09 - Medicina InternaAlcohol DrinkingMediterranean dietColorectal cancerMedicine (miscellaneous)Context (language use)Motor ActivityDiet MediterraneanRisk FactorsSurveys and QuestionnairesInternal medicinemedicineHumansFamily historySettore MED/49 - Scienze Tecniche Dietetiche ApplicateLife StyleAgedNutrition and Dieteticsmediterranean diet colorectal cancer diabetes obesity Sicilybusiness.industrySmokingCase-control studyCancerFeeding BehaviorOdds ratioMiddle Agedmedicine.diseaseObesityHealthy VolunteersLogistic ModelsItalySocioeconomic FactorsOncologyCase-Control StudiesMultivariate AnalysisPatient ComplianceFemaleColorectal Neoplasmsbusiness
researchProduct